文献速递浆细胞疾病

卡非佐米、来那度胺和地塞米松方案改善复发或难治性多发性骨髓瘤患者的总生存期

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
PubMed 文献 · J Clin Oncol · 2018-01-17

ASPIRE研究比较卡非佐米联合来那度胺和地塞米松(KRd)与来那度胺加地塞米松(Rd)在复发或难治性多发性骨髓瘤患者中的疗效。预设分析报告最终总生存(OS)数据:KRd组中位OS为48.3个月,Rd组为40.4个月(HR 0.79;95%CI 0.67-0.95;单侧P=0.0045),KRd组死亡风险显著降低,生存期延长7.9个月,首次复发时疗效优势最明显。

要点

  • KRd组中位OS为48.3个月,Rd组为40.4个月,HR 0.79(95%CI 0.67-0.95;单侧P=0.0045)。
  • 接受一线既往治疗者KRd较Rd中位OS延长11.4个月;接受≥二线者延长6.5个月。
  • KRd组≥3级不良事件发生率为87.0%,Rd组为83.3%;因不良事件停药率分别为19.9%和21.5%。

核心结论

  • KRd方案较Rd方案在复发或难治性多发性骨髓瘤患者中显著且具有临床意义地降低死亡风险,生存期延长7.9个月,首次复发时疗效优势最明显。

研究设计与样本

  • ASPIRE研究为随机、开放标签、1:1对照研究,纳入既往接受1-3线治疗的复发多发性骨髓瘤成人患者,比较KRd与Rd方案(28天为一周期,18周期后所有患者仅接受Rd),主要终点为无进展生存期,OS为关键次要终点。

主要发现

  • KRd组中位OS为48.3个月(95%CI 42.4-52.8个月),Rd组为40.4个月(95%CI 33.6-44.4个月),HR 0.79(95%CI 0.67-0.95;单侧P=0.0045)。
  • 接受一线既往治疗的患者中,KRd组中位OS较Rd组延长11.4个月;接受≥二线既往治疗的患者中,KRd组较Rd组延长6.5个月。
  • 因不良事件停药率KRd组为19.9%,Rd组为21.5%。
  • ≥3级不良事件发生率KRd组为87.0%,Rd组为83.3%。
  • 选定的≥3级不良事件(KRd vs Rd):急性肾衰竭3.8% vs 3.3%,心力衰竭4.3% vs 2.1%,缺血性心脏病3.8% vs 2.3%,高血压6.4% vs 2.3%,血小板减少20.2% vs 14.9%,周围神经病变2.8% vs 3.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma, progression-free survival was significantly improved in the carfilzomib group (hazard ratio, 0.69; two-sided P < .001). This prespecified analysis reports final overall survival (OS) data and updated safety results. Patients and Methods Adults with relapsed multiple myeloma (one to three prior lines of therapy) were eligible and randomly assigned at a one-to-one ratio to receive KRd or Rd in 28-day cycles until withdrawal of consent, disease progression, or occurrence of unacceptable toxicity. After 18 cycles, all patients received Rd only. Progression-free survival was the primary end point; OS was a key secondary end point. OS was compared between treatment arms using a stratified log-rank test. Results Median OS was 48.3 months (95% CI, 42.4 to 52.8 months) for KRd versus 40.4 months (95% CI, 33.6 to 44.4 months) for Rd (hazard ratio, 0.79; 95% CI, 0.67 to 0.95; one-sided P = .0045). In patients receiving one prior line of therapy, median OS was 11.4 months longer for KRd versus Rd; it was 6.5 months longer for KRd versus Rd among patients receiving ≥ two prior lines of therapy. Rates of treatment discontinuation because of adverse events (AEs) were 19.9% (KRd) and 21.5% (Rd). Grade ≥ 3 AE rates were 87.0% (KRd) and 83.3% (Rd). Selected grade ≥ 3 AEs of interest (grouped terms; KRd v Rd) included acute renal failure (3.8% v 3.3%), cardiac failure (4.3% v 2.1%), ischemic heart disease (3.8% v 2.3%), hypertension (6.4% v 2.3%), hematopoietic thrombocytopenia (20.2% v 14.9%), and peripheral neuropathy (2.8% v 3.1%). Conclusion KRd demonstrated a statistically significant and clinically meaningful reduction in the risk of death versus Rd, improving survival by 7.9 months. The KRd efficacy advantage is most pronounced at first relapse.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018. PMID: 29341834. doi:10.1200/JCO.2017.76.5032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。